Temafloxacin

Summary

Temafloxacin (CHEMBL277100) is an approved small molecule (ATC J01MA05); indicated across 1 condition including bacterial infectious disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01MA05
• Indications: 1 condition
• Chemistry: 417.4 Da · C21H18F3N3O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL277100
Name	Temafloxacin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	60021
ChEBI	CHEBI:77796
ATC	J01MA05
Molecular formula	C21H18F3N3O3
Molecular weight	417.4
InChIKey	QKDHBVNJCZBTMR-UHFFFAOYSA-N

SMILES: CC1CN(CCN1)C2=C(C=C3C(=C2)N(C=C(C3=O)C(=O)O)C4=C(C=C(C=C4)F)F)F

IUPAC name: 1-(2,4-difluorophenyl)-6-fluoro-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid

ChEBI definition: A quinolone that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted at positions 1, 6, and 7 by 2,4-difluorophenyl, fluorine, and 3-methylpiperazin-1-yl groups, respectively.

Also known as: Temafloxacin, Temafloxacine, Temafloxacino, TEMAFLOXACINE, SID144206857, TEMAFLOXACIN

Parent form; salt/anhydrous children: CHEMBL2107495

Patent coverage: 2,617 distinct patent families (10,130 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 10,122 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).